Verastem, Inc.
AVMAPKI FAKZYNJA CO-PACK
KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Continue to pursue regulatory paths for potential expansion of the product launch into Europe and Japan.”